| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $44K | — | -98.6% |
| SG&A Expense | $3.4M | — | +53.7% |
| Operating Income | -$6.9M | — | -28.1% |
| Income Tax | $339 | — | — |
| Net Income | -$6.4M | — | -41.0% |
| EPS (Basic) | -$0.14 | — | +12.5% |
| EPS (Diluted) | -$0.14 | — | +12.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $0 | — | — |
| Current Assets | $35.3M | +264.0% | +197.7% |
| Total Assets | $35.3M | +264.0% | +197.7% |
| Current Liabilities | $6.3M | +8.3% | +25.0% |
| Total Liabilities | $7.6M | +3.2% | +9.2% |
| Stockholders' Equity | $27.8M | +1068.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.3M | — | -26.4% |
| Financing Cash Flow | $31.1M | — | +468.6% |
| +461.7% |